SYDNEY, AUSTRALIA--(Marketwire - Jun 12, 2012) - Prima BioMed Ltd (
Webcast link
Shareholders who are unable to attend the meeting and wish to view the proceedings on the Webcast should use the following link:
http://events.knowledgevision.com/staging/The_Prima_Biomed_Shareholder_Briefing.html
Shareholders who would also like to ask a question at the meeting are requested to dial in on one of the following numbers:
Dial in Numbers:
| Australia Toll Free | 1 800 131 617 |
| Australia Alternate Toll Free | 1 800 838 758 |
| Canada/USA | 1 855 624 0077 |
| China Wide | 10 800 140 1776 |
| France | 0800 913 734 |
| Germany | 0800 183 0918 |
| Hong Kong | 0800 968 273 |
| India | 0008 0010 08070 |
| Indonesia | 001 803 321 8057 |
| Ireland | 1800 948 607 |
| Japan | 006633 868000 |
| Malaysia | 1800 816 441 |
| New Zealand | 0800 452 795 |
| Singapore | 800 101 2702 |
| South Africa | 0800 984 013 |
| Switzerland | 0800 802 498 |
| Taiwan | 0080 112 7377 |
| UAE | 8000 3570 2706 |
| United Kingdom | 0800 051 1453 |
About Prima BioMed
Prima BioMed is a global biotechnology company headquartered in Australia. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer.
Contact Information:
For further information please contact:
Mr James Moses
Investor and Media Relations
Mandate Corporate
Ph: +61 (0) 420 991 574
E: